Search

Your search keyword '"Bahleda, Rastislav"' showing total 306 results
Start Over Author "Bahleda, Rastislav"
306 results on '"Bahleda, Rastislav"'

1. Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review

Author

Mathiot, Laurent, Baldini, Capucine, Letissier, Octave, Hollebecque, Antoine, Bahleda, Rastislav, Gazzah, Anas, Smolenschi, Cristina, Sakkal, Madona, Danlos, François-Xavier, Henon, Clémence, Beshiri, Kristi, Goldschmidt, Vincent, Parisi, Claudia, Patrikidou, Anna, Michot, Jean-Marie, Marabelle, Aurélien, Postel-Vinay, Sophie, Bernard-Tessier, Alice, Loriot, Yohann, Ponce, Santiago, Champiat, Stéphane, and Ouali, Kaïssa

Published
2024
Full Text
View/download PDF

2. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review

Author

Géraud, Arthur, Hueso, Thomas, Laparra, Ariane, Bige, Naike, Ouali, Kaissa, Cauquil, Cécile, Stoclin, Annabelle, Danlos, François-Xavier, Hollebecque, Antoine, Ribrag, Vincent, Gazzah, Anas, Goldschmidt, Vincent, Baldini, Capucine, Suzzoni, Steve, Bahleda, Rastislav, Besse, Benjamin, Barlesi, Fabrice, Lambotte, Olivier, Massard, Christophe, Marabelle, Aurélien, Castilla-Llorente, Cristina, Champiat, Stéphane, and Michot, Jean-Marie

Published
2024
Full Text
View/download PDF

3. Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs

Author

Henon, Clémence, Vibert, Julien, Eychenne, Thomas, Gruel, Nadège, Colmet-Daage, Léo, Ngo, Carine, Garrido, Marlène, Dorvault, Nicolas, Marques Da Costa, Maria Eugenia, Marty, Virginie, Signolle, Nicolas, Marchais, Antonin, Herbel, Noé, Kawai-Kawachi, Asuka, Lenormand, Madison, Astier, Clémence, Chabanon, Roman, Verret, Benjamin, Bahleda, Rastislav, Le Cesne, Axel, Mechta-Grigoriou, Fatima, Faron, Matthieu, Honoré, Charles, Delattre, Olivier, Waterfall, Joshua J., Watson, Sarah, and Postel-Vinay, Sophie

Published
2024
Full Text
View/download PDF

4. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, Funda, Bahleda, Rastislav, Hierro, Cinta, Sanson, Marc, Bridgewater, John, Arkenau, Hendrik-Tobias, Tran, Ben, Kelley, Robin Kate, Park, Joon Oh, Javle, Milind, He, Yaohua, Benhadji, Karim A, and Goyal, Lipika

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Breast Cancer, Prevention, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Agents, Bile Duct Neoplasms, Cholangiocarcinoma, Disease-Free Survival, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Pyrazoles, Pyrimidines, Pyrroles, Receptor, Fibroblast Growth Factor, Type 1, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized FGFR1-3 aberrations. The greatest activity was observed in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (ORR, 25.4%). Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib. Futibatinib demonstrated a manageable safety profile. The most common treatment-emergent adverse events were hyperphosphatemia (81.2%), diarrhea (33.5%), and nausea (30.4%). These results formed the basis for ongoing futibatinib phase II/III trials and demonstrate the potential of genomically selected early-phase trials to help identify molecular subsets likely to benefit from targeted therapy. SIGNIFICANCE: This phase I dose-expansion trial demonstrated clinical activity and tolerability of the irreversible FGFR1-4 inhibitor futibatinib across a broad spectrum of FGFR-aberrant tumors. These results formed the rationale for ongoing phase II/III futibatinib trials in cholangiocarcinoma, breast cancer, gastroesophageal cancer, and a genomically selected disease-agnostic population.This article is highlighted in the In This Issue feature, p. 275.

Published
2022

6. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Author

Baldini, Capucine, Danlos, Francois-Xavier, Varga, Andreea, Texier, Matthieu, Halse, Heloise, Mouraud, Severine, Cassard, Lydie, Champiat, Stéphane, Signolle, Nicolas, Vuagnat, Perrine, Martin-Romano, Patricia, Michot, Jean-Marie, Bahleda, Rastislav, Gazzah, Anas, Boselli, Lisa, Bredel, Delphine, Grivel, Jonathan, Mohamed-Djalim, Chifaou, Escriou, Guillaume, Grynszpan, Laetitia, Bigorgne, Amelie, Rafie, Saloomeh, Abbassi, Alae, Ribrag, Vincent, Postel-Vinay, Sophie, Hollebecque, Antoine, Susini, Sandrine, Farhane, Siham, Lacroix, Ludovic, Parpaleix, Aurelien, Laghouati, Salim, Zitvogel, Laurence, Adam, Julien, Chaput, Nathalie, Soria, Jean-Charles, Massard, Christophe, and Marabelle, Aurelien

Published
2022
Full Text
View/download PDF

8. Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

11. Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

12. Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

15. Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

16. Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

17. Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

19. Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

21. Data from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, primary, Braye, Floriane, primary, Vasseur, Damien, primary, Pradat, Yoann, primary, Bahleda, Rastislav, primary, Pobel, Cédric, primary, Bigot, Ludovic, primary, Déas, Olivier, primary, Florez Arango, Juan David, primary, Guaitoli, Giorgia, primary, Mizuta, Hayato, primary, Combarel, David, primary, Tselikas, Lambros, primary, Michiels, Stefan, primary, Nikolaev, Sergey I., primary, Scoazec, Jean-Yves, primary, Ponce-Aix, Santiago, primary, Besse, Benjamin, primary, Olaussen, Ken A., primary, Loriot, Yohann, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

23. Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

24. Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

25. Data from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, primary, Wagner, Andrew J., primary, Burgess, Melissa A., primary, Junker, Niels, primary, Chisamore, Michael, primary, Peterson, Patrick, primary, Szpurka, Anna M., primary, Ceccarelli, Matteo, primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

27. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Author

Schöffski, Patrick, primary, Bahleda, Rastislav, additional, Wagner, Andrew J., additional, Burgess, Melissa A., additional, Junker, Niels, additional, Chisamore, Michael, additional, Peterson, Patrick, additional, Szpurka, Anna M., additional, Ceccarelli, Matteo, additional, and Tap, William D., additional

Published
2023
Full Text
View/download PDF

28. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, additional, Braye, Floriane, additional, Vasseur, Damien, additional, Pradat, Yoann, additional, Bahleda, Rastislav, additional, Pobel, Cédric, additional, Bigot, Ludovic, additional, Déas, Olivier, additional, Florez Arango, Juan David, additional, Guaitoli, Giorgia, additional, Mizuta, Hayato, additional, Combarel, David, additional, Tselikas, Lambros, additional, Michiels, Stefan, additional, Nikolaev, Sergey I., additional, Scoazec, Jean-Yves, additional, Ponce-Aix, Santiago, additional, Besse, Benjamin, additional, Olaussen, Ken A., additional, Loriot, Yohann, additional, and Friboulet, Luc, additional

Published
2023
Full Text
View/download PDF

29. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Author

Bigot, Frédéric, Castanon, Eduardo, Baldini, Capucine, Hollebecque, Antoine, Carmona, Alberto, Postel-Vinay, Sophie, Angevin, Eric, Armand, Jean-Pierre, Ribrag, Vincent, Aspeslagh, Sandrine, Varga, Andrea, Bahleda, Rastislav, Menis, Jessica, Gazzah, Anas, Michot, Jean-Marie, Marabelle, Aurélien, Soria, Jean-Charles, and Massard, Christophe

Published
2017
Full Text
View/download PDF

30. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Author

Recondo, Gonzalo, Mahjoubi, Linda, Maillard, Aline, Loriot, Yohann, Bigot, Ludovic, Facchinetti, Francesco, Bahleda, Rastislav, Gazzah, Anas, Hollebecque, Antoine, Mezquita, Laura, Planchard, David, Naltet, Charles, Lavaud, Pernelle, Lacroix, Ludovic, Richon, Catherine, Lovergne, Aurelie Abou, De Baere, Thierry, Tselikas, Lambros, Deas, Olivier, Nicotra, Claudio, Ngo-Camus, Maud, Frias, Rosa L., Solary, Eric, Angevin, Eric, Eggermont, Alexander, Olaussen, Ken A., Vassal, Gilles, Michiels, Stefan, Andre, Fabrice, Scoazec, Jean-Yves, Massard, Christophe, Soria, Jean-Charles, Besse, Benjamin, and Friboulet, Luc

Published
2020
Full Text
View/download PDF

32. Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer

Author

Facchinetti, Francesco, primary, Hollebecque, Antoine, additional, Braye, Floriane, additional, Vasseur, Damien, additional, Pradat, Yoann, additional, Bahleda, Rastislav, additional, Pobel, Cédric, additional, Bigot, Ludovic, additional, Déas, Olivier, additional, Florez-Arango, Juan-David, additional, Guaitoli, Giorgia, additional, Mizuta, Hayato, additional, Combarel, David, additional, Tselikas, Lambros, additional, Michiels, Stefan, additional, Nikolaev, Sergey, additional, Scoazec, Jean-Yves, additional, Ponce-Aix, Santiago, additional, Besse, Benjamin, additional, Olaussen, Ken A., additional, Loriot, Yohann, additional, and Friboulet, Luc, additional

Published
2023
Full Text
View/download PDF

33. Supplementary Methods from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, Funda, primary, Bahleda, Rastislav, primary, Hierro, Cinta, primary, Sanson, Marc, primary, Bridgewater, John, primary, Arkenau, Hendrik-Tobias, primary, Tran, Ben, primary, Kelley, Robin Kate, primary, Park, Joon Oh, primary, Javle, Milind, primary, He, Yaohua, primary, Benhadji, Karim A., primary, and Goyal, Lipika, primary

Published
2023
Full Text
View/download PDF

35. Data from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table S1-S2 and Figure S1-S2 from Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Author

Karkera, Jayaprakash D., primary, Cardona, Gabriela Martinez, primary, Bell, Katherine, primary, Gaffney, Dana, primary, Portale, Joseph C., primary, Santiago-Walker, Ademi, primary, Moy, Christopher H., primary, King, Peter, primary, Sharp, Michael, primary, Bahleda, Rastislav, primary, Luo, Feng R., primary, Alvarez, John D., primary, Lorenzi, Matthew V., primary, and Platero, Suso J., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legends from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

40. Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, Funda, primary, Bahleda, Rastislav, primary, Hierro, Cinta, primary, Sanson, Marc, primary, Bridgewater, John, primary, Arkenau, Hendrik-Tobias, primary, Tran, Ben, primary, Kelley, Robin Kate, primary, Park, Joon Oh, primary, Javle, Milind, primary, He, Yaohua, primary, Benhadji, Karim A., primary, and Goyal, Lipika, primary

Published
2023
Full Text
View/download PDF

41. Data from Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Author

Karkera, Jayaprakash D., primary, Cardona, Gabriela Martinez, primary, Bell, Katherine, primary, Gaffney, Dana, primary, Portale, Joseph C., primary, Santiago-Walker, Ademi, primary, Moy, Christopher H., primary, King, Peter, primary, Sharp, Michael, primary, Bahleda, Rastislav, primary, Luo, Feng R., primary, Alvarez, John D., primary, Lorenzi, Matthew V., primary, and Platero, Suso J., primary

Published
2023
Full Text
View/download PDF

42. Figure S1B from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Author

Bahleda, Rastislav, primary, Italiano, Antoine, primary, Hierro, Cinta, primary, Mita, Alain, primary, Cervantes, Andres, primary, Chan, Nancy, primary, Awad, Mark, primary, Calvo, Emiliano, primary, Moreno, Victor, primary, Govindan, Ramaswamy, primary, Spira, Alexander, primary, Gonzalez, Martha, primary, Zhong, Bob, primary, Santiago-Walker, Ademi, primary, Poggesi, Italo, primary, Parekh, Trilok, primary, Xie, Hong, primary, Infante, Jeffrey, primary, and Tabernero, Josep, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure Legends from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Author

Sessa, Cristiana, primary, Lorusso, Patricia, primary, Tolcher, Anthony, primary, Farace, Françoise, primary, Lassau, Nathalie, primary, Delmonte, Angelo, primary, Braghetti, Antonio, primary, Bahleda, Rastislav, primary, Cohen, Patrick, primary, Hospitel, Marie, primary, Veyrat-Follet, Christine, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Data from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Author

Bahleda, Rastislav, primary, Italiano, Antoine, primary, Hierro, Cinta, primary, Mita, Alain, primary, Cervantes, Andres, primary, Chan, Nancy, primary, Awad, Mark, primary, Calvo, Emiliano, primary, Moreno, Victor, primary, Govindan, Ramaswamy, primary, Spira, Alexander, primary, Gonzalez, Martha, primary, Zhong, Bob, primary, Santiago-Walker, Ademi, primary, Poggesi, Italo, primary, Parekh, Trilok, primary, Xie, Hong, primary, Infante, Jeffrey, primary, and Tabernero, Josep, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Fig. S1 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Author

Sessa, Cristiana, primary, Lorusso, Patricia, primary, Tolcher, Anthony, primary, Farace, Françoise, primary, Lassau, Nathalie, primary, Delmonte, Angelo, primary, Braghetti, Antonio, primary, Bahleda, Rastislav, primary, Cohen, Patrick, primary, Hospitel, Marie, primary, Veyrat-Follet, Christine, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Text from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Author

Sessa, Cristiana, primary, Lorusso, Patricia, primary, Tolcher, Anthony, primary, Farace, Françoise, primary, Lassau, Nathalie, primary, Delmonte, Angelo, primary, Braghetti, Antonio, primary, Bahleda, Rastislav, primary, Cohen, Patrick, primary, Hospitel, Marie, primary, Veyrat-Follet, Christine, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table S1 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Author

Sessa, Cristiana, primary, Lorusso, Patricia, primary, Tolcher, Anthony, primary, Farace, Françoise, primary, Lassau, Nathalie, primary, Delmonte, Angelo, primary, Braghetti, Antonio, primary, Bahleda, Rastislav, primary, Cohen, Patrick, primary, Hospitel, Marie, primary, Veyrat-Follet, Christine, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Author

Le Tourneau, Christophe, primary, Tao, Yungan, primary, Gomez-Roca, Carlos, primary, Cristina, Valerie, primary, Borcoman, Edith, primary, Deutsch, Eric, primary, Bahleda, Rastislav, primary, Calugaru, Valentin, primary, Modesto, Anouchka, primary, Rouits, Elisabeth, primary, Gollmer, Kathrin, primary, Vuagniaux, Gregoire, primary, Crompton, Philippa, primary, Zanna, Claudio, primary, Szyldergemajn, Sergio, primary, Delord, Jean-Pierre, primary, and Bourhis, Jean, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results